Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

BACKGROUND: We investigated the effect of crenezumab, a humanized anti-amyloid-beta (Aβ) immunoglobulin (Ig)G4 monoclonal antibody, on biomarkers of amyloid pathology, neurodegeneration, and disease progression in patients with mild-to-moderate Alzheimer’s disease (AD). METHODS: This double-blind, p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Alzheimers Res Ther
Main Authors: Salloway, Stephen, Honigberg, Lee A., Cho, William, Ward, Michael, Friesenhahn, Michel, Brunstein, Flavia, Quartino, Angelica, Clayton, David, Mortensen, Deborah, Bittner, Tobias, Ho, Carole, Rabe, Christina, Schauer, Stephen P., Wildsmith, Kristin R., Fuji, Reina N., Suliman, Shehnaaz, Reiman, Eric M., Chen, Kewei, Paul, Robert
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6146627/
https://ncbi.nlm.nih.gov/pubmed/30231896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-018-0424-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados